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Dr. Ross raises the very valuable point that pa-
tients with cardiac arrest who are far from emer-
gency medical services may be at elevated risk, as 
compared with those living in a city. As such, the 
availability of an AED in the home might have 
particular value for a patient living in a rural area 
or in an area where emergency services are sub-
optimal. In our study, the number of events was 
too low to address this question in a definitive 
manner, but we can say that the rescue of patients 
with cardiac arrest by spouses certainly did occur 
in rural settings and far from medical aid. It is 
unlikely these patients would have survived ven-
tricular fibrillation without an AED.
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HSV-2 Suppression and the Incidence of HIV
To the Editor: Watson-Jones et al. (April 10 
issue)1 report that the suppression of herpes sim-
plex virus type 2 (HSV-2) does not decrease the in-
cidence of human immunodeficiency virus (HIV) 
infection in female workers at recreational facili-
ties in northwestern Tanzania. However, this find-
ing is disputable, since treatment with 400 mg of 
acyclovir twice daily did not suppress the inci-
dence of HSV-2 infection. Any conclusion regard-
ing the preventive effect of acyclovir should be 
based on the analysis of patients in whom the 
drug was detected, since the study is confounded 
because a majority of patients in the acyclovir group 
tested negative for acyclovir (>65%) at both 12 
months and 24 months. Similarly, the data on 
HIV acquisition should be evaluated according to 
the suppression of the HSV-2 viral load, as com-
pared with baseline. We believe that the study’s 
methodologic limitations prevent drawing any con-
clusions about the effect of acyclovir on HIV ac-
quisition.2
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The authors reply: We do not conclude that 
HSV-2 suppression is ineffective in the prevention 
of HIV acquisition but rather that suppressive ther-
apy did not reduce the incidence of HIV acquisition 
in our study population. Despite intensive adher-
ence support, study participants found it difficult 
to adhere to twice-daily use of acyclovir over a pro-
longed period. This finding is important, since it 
shows the limitations of this intervention as a 
practical measure in HIV control. Our results have 
been confirmed by a further trial showing no ef-
fect of acyclovir therapy on HIV incidence.1
Lisco and Vanpouille suggest that we should 
have restricted our analysis to patients in whom 
acyclovir was detected. Urine testing for acyclovir 
was done as a process measure in a small sam-
ple of subjects at selected time points. The pres-
ence of acyclovir at one time point is not a proxy 
for overall adherence during the trial. Similarly, 
HSV-2 shedding was measured only at certain vis-
its, and there were too few subjects with shedding 
to conduct a subgroup analysis of HIV incidence. 
In any case, such analyses would have been sub-
ject to severe confounding, since an equivalent 
restriction would not have been possible in the 
placebo group, thus resulting in loss of the com-
parability provided by randomization.
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